Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Adult Subjects
People with Relapsed or Refractory T or B Cell Malignancies are asked to participate in a research study being conducted by Montefiore Medical Center.
You may be eligible to participate in this study if you:
• Are a male or female at least 18 years of age and body weight ≥60 kg
• Have confirmed diagnosis of a T cell malignancy
• Have CD70-expressing tumors
• Have adequate organ function
You may NOT participate in this study if you:
• Have received prior treatment with anti-CD70 targeting agents
• Have clinical signs of HLH
• Have an uncontrolled, acute, life-threatening bacterial, viral, or fungal infection
• Have an unstable angina, arrhythmia, or myocardial infarction
• Have had prior solid organ transplantation
• Have known immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C virus
• Are pregnant or breastfeeding
Contact Information
Joel Victor, Study Coordinator
111 E. 210th Street Bronx, NY 10467
Phone: (718) 920-6680
Email: JOVICTOR@MONTEFIORE.ORG